Lake Street Maintains Buy on Kyntra Bio, Lowers Price Target to $8
Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.
Follow the latest Kyntra Bio, Inc. (KYNB) news and market headlines alongside the live KYNB price. Stay informed on what's moving KYNB.
Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q3 earnings
Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.
HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.42) per share which beat the analyst consensus estimate of $(3.55) by 3.66 percent. This is a 5.23 percent decrease over losses of $(3.25) per share from the
Adherex Technologies reported Q3 2026 earnings of $0.12 per share, beating consensus estimates of $0.09, with a 33.33% earnings surprise. Revenues reached $19.61 million, surpassing estimates by 3.69% and growing 57.4% year-over-year. The stock has gained 38.2% year-to-date, outperforming the S&P 500's 11.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to KYNB, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.